Back to today’s briefing

Story perspectives

FDA Rejects Replimune's Melanoma Treatment Amid Data Concerns

7/22/2025

44 6

Summary

Story summary

In a significant setback, the FDA has turned down Replimune's RP1 treatment for advanced melanoma, pointing to insufficient trial data and varied patient responses. While safety wasn't a concern, the trial's design faced scrutiny. Replimune is now eager to explore accelerated approval pathways, highlighting the desperate need for effective therapies for these patients.

1 of 1

Story summary

In a significant setback, the FDA has turned down Replimune's RP1 treatment for advanced melanoma, pointing to insufficient trial data and varied patient responses. While safety wasn't a concern, the trial's design faced scrutiny. Replimune is now eager to explore accelerated approval pathways, highlighting the desperate need for effective therapies for these patients.